


Acute Kidney Injury Clinical Pathway



		Ciliii	carratiiway			
Provi	Provisional diagnosis		Previous lab investigations if any:			
	□Hypertension	□COPD	□Immunocom	promised	□Post-Transplant	
CO-MORBIDS	☐Type 2 Diabetes Mellitus	□CLD	■Malignancy /	' Chemo Tx	□Alcoholic	
	□CAD	□ CKD		muno suppressant	□Smoker	
	Increase in Serum Creatinine Increase in Creatinine Urine output <0.5ml/k	by 1.5 times th	ne baseline within 7 da ours (KDIGO - Appendi	ys, Baseline Cre x 1)		
Caus	USG abdomen for Ren Normal in size and Grade 1 RPC Grade 2 RPC Grade 3 RPC		changes:			
	o Source:		CRITICAL CAR	E		
	Blood and product transfusions:					
	Hypovolemia	Poluc:	Maintonanco			
	Sepsis	บบเนร	Maintenance			
	o Source:					
	Antibiotics:					
	Nephrotoxic drugs					
	Drug responsib	le:				

Contrast Associated - AKI (CA-AKI) O IV fluids: ______ (O NS O NaHCO₃ – Appendix 1 for dose and duration) Appendix 2 Hepatorenal Albumin Terlipressin



Start RRT

Worsening acidosis Ph<7.25

Persistent/worsening oliguria
Other solute complications

Management:

Cause managed as per previous section All drug doses adjusted as per EGFR

Renal Replacement Therapy:

Urine output <0.5ml/kg/hr for >6 hrs

Metabolic acidosis in ABG despite of medical management.

Hyperkalemia K> 6Meq/L despite anti hyperkalemic measures,

If any 1 present, consider Renal replacement Therapy

Hemodynamically stable:

Yes IHD/SLED

No SLED/ CRRT (Refer to CRRT pathway)

Dialysis catheter location in the order of preference:

RIJV If not cannulated, reason: Femoral (Rt. or Lt.) If not cannulated, reason: LIJV If not cannulated, reason:

Subclavian

Other location, please mention:

Efficacy:

Dialysis adequate?

Duration of dialysis in hours ___

Metabolic acidosis corrected

Potassium levels < 5.5

Calculate Kt/V if possible: (target >1.2)

If CRRT, Effluent 20-25ml/kg/hour

Anticoagulation:

Coagulopathy

Yes:

IHD/SLED: Nil

CRRT: Regional Citrate anticoagulation

No:

IHD/SLED: Unfractionated Heparin CRRT: Regional Citrate Anticoagulation

If Citrate anticoagulation: (Refer to CRRT pathway)

Ionized calcium levels:

Assessment:

Urine output > 400ml/day
Electrolytes normal
No metabolic acidosis in ABG
If possible, Urine creatinine clearance >15ml/min

Can wait on RRT and reassess



ICU Days	EVENTS / SUPPORTS					
1	□MV	□RRT	□Vasopressors	□Organ dysfunction	□Others	
2	□MV	□RRT	□Vasopressors	□Organ dysfunction	□Others	
3	■MV	□RRT	□Vasopressors	□Organ dysfunction	Others	
4	□MV	□RRT	□Vasopressors	□Organ dysfunction	□Others	
5	□MV	□RRT	□Vasopressors	□Organ dysfunction	□Others	
6	□MV	□RRT	□Vasopressors	□Organ dysfunction	□Others	
7	□MV	□RRT	□Vasopressors	□Organ dysfunction	□Others	
>7 days Course of illness						
			3333			

<u>Outcome</u>

I.	APACHE II/IV Score:, 48hr:			
	at the time of transfer out / LAMA / Discharge: 3. Length of ICU			
	Stay: 4.Length of Hospital stay:			
II.	Organ Failure : □AKI □Liver failure □Coagulopathy □Encephalopathy			
	■Myocardial Dysfunction ■CIPNM ■MV dependent			
III.	Renal replacement therapyday from CRRT / SLED			
IV.	MVduration □Proning □ECMO □Tracheostomy			
٧.	Outcome: Death Survived (Discharged from ICU / Transfer out to stepdown /			
	HDU/ Room) □LAMA			
□Ambulated □Bed ridden (with support / without support)				
Doctor Name:, Sign:				

Appendix 1:

Definition and staging of AKI

AKI is defined as any of the following (Not Graded):

- Increase in SCr by X0.3 mg/dl (X26.5 lmol/l) within 48 hours; or
- Increase in SCr to X1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
- Urine volume o0.5 ml/kg/h for 6 hours.

Staging of AKI

Stage	Serum creatinine	Urine output
1	1.5–1.9 times baseline OR ≥0.3 mg/dl (≥26.5 μmol/l) increase	<0.5 ml/kg/h for 6–12 hours
2	2.0-2.9 times baseline	$<$ 0.5 ml/kg/h for \geqslant 12 hours
3	3.0 times baseline OR Increase in serum creatinine to ≥ 4.0 mg/dl (≥ 353.6 µmol/l) OR Initiation of renal replacement therapy OR, In patients < 18 years, decrease in eGFR to < 35 ml/min per 1.73 m²	<0.3 ml/kg/h for ≥24 hours OR Anuria for ≥12 hours

Appendix 2

At-risk patients for CAN:

- •All patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² who have significant proteinuria (defined as albuminuria >300 mg/day, which corresponds to proteinuria > 500 mg/day).
- •All patients with eGFR <60 mL/min/1.73 m² and comorbidities including diabetes, heart failure, liver failure, or multiple myeloma.
- •All patients with eGFR <45 mL/min/1.73/m² even in the absence of proteinuria or any other comorbidities.
- •Patients who have eGFR <45 mL/min/1.73 m² and have proteinuria and diabetes or other comorbidities and all patients with eGFR <30 mL/min/1.73 m² should be considered at highest risk.

Fluid administration — For all at-risk patients undergoing procedures involving intra-arterial contrast administration, if there are no contraindications to volume expansion, we administer intravenous isotonic <u>saline</u> prior to and continued for several hours after contrast administration.

Preferred Protocol:

Outpatients — We give 3 mL/kg over one hour pre procedure and 1 to 1.5 ml/kg/hour during and for 4- 6 hours post procedure(6ml/kg post procedure)

Inpatients: We give 1 mL/kg/hour for 6-12 hours pre procedure, during and for 6-12 hours post procedure.

Author	Supervised by	Version/Date	Review Date
Dr. SriCharan Goda	Dr. Masood Mohammed	1.0/28-02-2023	28-02-2025
MD, IDCCM	MD,MRCP(UK),EDIC,FICCM(UK)		